ÂÜÀòÂÒÂ×

Mark is an experienced safety pharmacologist & toxicologist, with extensive knowledge and expertise in managing preclinical development programmes for both small molecules and biologics gained in both contract research organizations and the pharmaceutical industry, from small start-ups to mid - large Pharma. In this, he has held senior positions at Huntingdon Life Sciences Ltd (Team Leader, 1997 – 1999); H. Lundbeck A/S Denmark (Academic Associate, 1999-2004); AstraZenica AB, Sweden (Assoc. Principal Scientist, 2004-2008); PanGenetics UK Ltd, UK (Preclinical Development Manager, 2008 – 2010). In 2010, Mark founded Pharm Tox Consulting Ltd, UK and is currently serving as an independent consultant to large and early-stage biotech companies such as ATXA. Mark’s experience includes developing early discovery efficacy models to screen lead candidates, late discovery safety screening and all areas of preclinical development and early clinical development.

Furthermore, his experience extends to regulatory submission, including preparation of formal responses to regulatory questions. He has worked in safety assessment across many therapeutic areas including cancer, cardiovascular, gastrointestinal, CNS, Immunology and Inflammation/Pain research areas. Mark has a keen interest in the development, validation and introduction of new models to aid drug discovery and the drug development process with particular focus in immunology, cardiovascular and CNS safety assessment. In Sept’ 2019, Mark joined ATXA as a consultant safety pharmacologist and toxicologist, advising the company on its ongoing late-stage preclinical development path, particularly in relation to the safety pharmacology and toxicology program as well as ensuring regulatory compliance.